Cargando…
Exploration of Clinical Breakpoint of Danofloxacin for Glaesserella parasuis in Plasma and in PELF
Background: In order to establish the clinical breakpoint (CBP) of danofloxacin against G. parasuis, three cutoff values, including epidemiological cutoff value (ECV), pharmacokinetic-pharmacodynamic (PK-PD) cutoff value (CO(PD)) and clinical cutoff value (CO(CL)), were obtained in the present study...
Autores principales: | Xu, Zihui, Huang, Anxiong, Luo, Xun, Zhang, Peng, Huang, Lingli, Wang, Xu, Mi, Kun, Fang, Shiwei, Huang, Xiao, Li, Jun, Yuan, Zonghui, Hao, Haihong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8300709/ https://www.ncbi.nlm.nih.gov/pubmed/34356730 http://dx.doi.org/10.3390/antibiotics10070808 |
Ejemplares similares
-
Dosing Regimen of Aditoprim and Sulfamethoxazole Combination for the Glaesserella parasuis Containing Resistance and Virulence Genes
por: Huang, Anxiong, et al.
Publicado: (2022) -
Rational Use of Danofloxacin for Treatment of Mycoplasma gallisepticum in Chickens Based on the Clinical Breakpoint and Lung Microbiota Shift
por: Wang, Shuge, et al.
Publicado: (2022) -
Evidence for Establishing the Clinical Breakpoint of Cefquinome against Haemophilus Parasuis in China
por: Mi, Kun, et al.
Publicado: (2021) -
Optimal Regimens and Clinical Breakpoint of Avilamycin Against Clostridium perfringens in Swine Based on PK-PD Study
por: Huang, Anxiong, et al.
Publicado: (2022) -
The Glaesserella parasuis phosphoglucomutase is partially required for lipooligosaccharide synthesis
por: Feng, Saixiang, et al.
Publicado: (2020)